URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Jay Parrish Biography and Net Worth

Insider of Vir Biotechnology

Jay Parrish, Ph.D., has served as our Chief Business Officer since July 2017 and is one of our co-founders. Prior to that, Dr. Parrish served as our Senior Vice President, Strategy and Corporate Development, from April 2017 to July 2017. Dr. Parrish is a Venture Partner at ARCH Venture Partners where he has served since May 2016. From September 2011 to May 2016, Dr. Parrish served in Gilead Sciences, Inc.’s Corporate Development group, where he was involved in building Gilead’s oncology and infectious disease portfolio, ultimately leading infectious disease business development for the company. Dr. Parrish also served as a scientist in Gilead’s medicinal chemistry group, from March 2004 to September 2011. Since 2012, Dr. Parrish has served as a part-time instructor at UC Berkeley Extension, where he teaches chemistry to undergraduates and post-baccalaureates. He also previously completed a postdoctoral fellowship at the Scripps Research Institute. Dr. Parrish received his B.S. in Chemistry from Emory University, a Ph.D. in Synthetic Organic Chemistry from the University of South Florida and an M.B.A. from the University of California, Berkeley Haas School of Business.

What is Jay Parrish's net worth?: The estimated net worth of Jay Parrish is at least $1.65 million as of February 1st, 2021. Dr. Parrish owns 224,536 shares of Vir Biotechnology stock worth more than $1,648,094 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Parrish may own. Learn More about Jay Parrish's net worth.
How do I contact Jay Parrish?: The corporate mailing address for Dr. Parrish and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Jay Parrish's contact information.
Has Jay Parrish been buying or selling shares of Vir Biotechnology?: Jay Parrish has not been actively trading shares of Vir Biotechnology in the last ninety days. Most recently, Jay Parrish sold 6,944 shares of the business's stock in a transaction on Monday, February 1st. The shares were sold at an average price of $69.91, for a transaction totalling $485,455.04. Following the completion of the sale, the insider now directly owns 224,536 shares of the company's stock, valued at $15,697,311.76. Learn More on Jay Parrish's trading history.
Who are Vir Biotechnology's active insiders?: Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?: In the last twelve months, insiders at the sold shares 14 times. They sold a total of 172,847 shares worth more than $1,697,678.88. The most recent insider tranaction occured on December, 2nd when EVP Verneuil Vanina De sold 76 shares worth more than $624.72. Insiders at Vir Biotechnology own 15.6% of the company. Learn More about insider trades at Vir Biotechnology.
Information on this page was last updated on 12/2/2024.

Jay Parrish Insider Trading History at Vir Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/1/2021	Sell	6,944	$69.91	$485,455.04	224,536
12/1/2020	Sell	6,945	$31.53	$218,975.85	226,852
11/2/2020	Sell	6,944	$31.27	$217,138.88	226,851
10/1/2020	Sell	6,945	$34.75	$241,338.75	226,852
8/3/2020	Sell	11,110	$47.65	$529,391.50
7/1/2020	Sell	75,000	$37.95	$2,846,250.00	248,147
6/1/2020	Sell	75,000	$35.22	$2,641,500.00	297,222
5/14/2020	Sell	75,000	$30.05	$2,253,750.00	297,222

Jay Parrish Buying and Selling Activity at Vir Biotechnology

Vir Biotechnology Company Overview

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Today's Range

Now: $7.34

$7.23

$7.56

50 Day Range

MA: $8.02

$6.74

$10.17

2 Week Range

Now: $7.34

$6.56

$13.09

Volume

3,745,310 shs

Average Volume

1,084,083 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

AI breakthrough about to upend industry

From Porter & Company | Ad

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.